Economic Analysis Supports Formulary Shift to Biosimilar Denosumab

FDA Quietly Approves Denosumab Biosimilars, Issues Interchangeability for Others

November 13th 2025

By Skylar Jeremias

FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.

Global Data Show Variety in Adalimumab Biosimilar Design, Patient Support Systems

November 7th 2025

By Skylar Jeremias

New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences.

Biosimilar Monthly Roundup: October 2025

November 6th 2025

By Skylar Jeremias

October 2025 marks a transformative period for biosimilars, with new FDA guidelines accelerating approvals and promising significant cost savings for health care.

Data Confirm Biosimilar Bmab 1200 Performance in Psoriasis Through 1 Year

November 6th 2025

By Skylar Jeremias

New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating moderate to severe plaque psoriasis.

UK Experts Publish Guidance on JC Virus Testing for Natalizumab Biosimilar Tyruko

November 5th 2025

By Skylar Jeremias

UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing safety and monitoring challenges.

Global Regulatory Gridlock Hinders Biosimilar Savings, Expert Panel Warns

November 4th 2025

By Skylar Jeremias

A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.

A Closer Look at New FDA Guidance Removing Barriers to Biosimilar Development

October 30th 2025

By Skylar Jeremias

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability.

BioRationality: The FDA Sets Sights on Removing Clinical Efficacy Studies for Biosimilars

October 29th 2025

By Sarfaraz K. Niazi, PhD

Biosimilars Improve Health System Resilience in Latin American, Caribbean Nations

October 28th 2025

By Skylar Jeremias

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for chronic conditions and oncology.

Comparable Insulin Glargine Biosimilar Could Help Relieve Diabetes Costs

October 27th 2025

By Skylar Jeremias